Van Birgelen A P, Van der Kolk J, Fase K M, Bol I, Poiger H, Van den Berg M, Brouwer A
Research Institute of Toxicology, University of Utrecht, The Netherlands.
Toxicol Appl Pharmacol. 1994 Jun;126(2):202-13. doi: 10.1006/taap.1994.1109.
Interactive effects on toxicity and biochemical parameters were studied between 2,3,3',4,4',5-hexachlorobiphenyl (PCB 156) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in a 13-week feeding study of female Sprague-Dawley rats. The diets were supplemented with PCB 156 (1.2, 6, or 12 mg/kg), with TCDD (5 micrograms/kg), or with combinations of both compounds. Estimated daily intake of 365 micrograms/kg body wt/day (6 mg/kg diet group) of PCB 156 caused a decrease in body weight gain, thymic atrophy, liver enlargement, a loss in hepatic retinoids, induction of CYP2B activity, and a decrease in plasma thyroxine concentrations. At an estimated daily intake of 81 micrograms PCB 156/kg body wt/day CYP1A1 and CYP1A2 activities were induced. Compared to a simultaneous subchronic feeding study with TCDD a toxic equivalency factor (TEF) between 0.00004 and 0.001 was estimated for PCB 156 with respect to the mentioned effects. Antagonistic effects were found between TCDD and PCB 156 for CYP2B activity and hepatic retinol levels. These effects concurred with a PCB 156 dose-dependent decrease in hepatic TCDD levels. Hepatic PCB 156 levels were found to be increased at the 1.2-mg PCB 156/kg dose group in coadministration with TCDD. In conclusion, at least part of the antagonistic effects between PCB 156 and TCDD observed have a toxico-kinetic base. Furthermore, the magnitude of the antagonistic effects may be neglected in comparison with the uncertainty in the TEF value. Therefore, the interactive effects found between PCB 156 and TCDD may have no implications for the additivity of the TEF concept.
在一项为期13周的雌性斯普拉格 - 道利大鼠喂养研究中,研究了2,3,3',4,4',5 - 六氯联苯(PCB 156)和2,3,7,8 - 四氯二苯并 - p - 二恶英(TCDD)对毒性和生化参数的交互作用。饮食中添加了PCB 156(1.2、6或12毫克/千克)、TCDD(5微克/千克)或两种化合物的组合。估计每日摄入量为365微克/千克体重/天(6毫克/千克饮食组)的PCB 156导致体重增加减少、胸腺萎缩、肝脏肿大、肝脏类视黄醇损失、CYP2B活性诱导以及血浆甲状腺素浓度降低。在估计每日摄入量为81微克PCB 156/千克体重/天时,CYP1A1和CYP1A2活性被诱导。与同时进行的TCDD亚慢性喂养研究相比,就上述影响而言,PCB 156的毒性当量因子(TEF)估计在0.00004至0.001之间。发现TCDD和PCB 156对CYP2B活性和肝脏视黄醇水平具有拮抗作用。这些影响与肝脏中TCDD水平随PCB 156剂量的降低一致。在与TCDD共同给药的1.2毫克PCB 156/千克剂量组中,发现肝脏中PCB 156水平升高。总之,观察到的PCB 156和TCDD之间的拮抗作用至少部分具有毒代动力学基础。此外,与TEF值的不确定性相比,拮抗作用的程度可能可忽略不计。因此,PCB 156和TCDD之间发现的交互作用可能对TEF概念的可加性没有影响。